VBIV logo

VBI Vaccines (VBIV) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 April 2010

Indexes:

Not included

Description:

VBI Vaccines is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases and cancer. They use advanced technology to create safe and effective vaccine candidates, aiming to improve global health and address unmet medical needs.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Aug 14, 2024

Recent annual earnings:

Apr 16, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 12, 2023

Analyst ratings

Recent major analysts updates

13 Apr '23 Raymond James
Outperform
11 Nov '22 Raymond James
Outperform
09 Aug '22 Raymond James
Strong Buy
08 Mar '22 Raymond James
Strong Buy
27 Aug '20 Raymond James
Strong Buy
22 July '20 Raymond James
Outperform
14 Nov '19 Raymond James
Outperform
16 Jan '19 Oppenheimer
Outperform
27 July '18 BMO Capital
Outperform
15 Nov '17 BMO Capital
Outperform

Screeners with VBIV included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

VBI Vaccines' pan-coronavirus vaccine candidate produced broad protection against variants of concern
VBI Vaccines' pan-coronavirus vaccine candidate produced broad protection against variants of concern
VBI Vaccines' pan-coronavirus vaccine candidate produced broad protection against variants of concern
VBIV
Market Watch27 September 2023

VBI Vaccines Inc. said Wednesday the first clinical data from a Phase I trial of a pan-coronavirus vaccine candidate produced broad and durable protection against variants of concern.

Why Is VBI Vaccines (VBIV) Stock Down 40% Today?
Why Is VBI Vaccines (VBIV) Stock Down 40% Today?
Why Is VBI Vaccines (VBIV) Stock Down 40% Today?
VBIV
InvestorPlace06 July 2023

VBI Vaccines (NASDAQ: VBIV ) stock is taking a beating on Thursday after the pharmaceutical company announced two stock offerings. VBI Vaccines announced both a public stock offering and a registered directing offering for shares of VBIV stock.

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
VBIV
Zacks Investment Research15 May 2023

VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to loss of $2.40 per share a year ago.

VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
VBIV
Zacks Investment Research05 April 2023

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split
VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split
VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split
VBIV
Market Watch04 April 2023

VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct a reverse stock split. Cambridge, Mass.

FAQ

  • What is the primary business of VBI Vaccines?
  • What is the ticker symbol for VBI Vaccines?
  • Does VBI Vaccines pay dividends?
  • What sector is VBI Vaccines in?
  • What industry is VBI Vaccines in?
  • What country is VBI Vaccines based in?
  • When did VBI Vaccines go public?
  • Is VBI Vaccines in the S&P 500?
  • Is VBI Vaccines in the NASDAQ 100?
  • Is VBI Vaccines in the Dow Jones?
  • When was VBI Vaccines's last earnings report?
  • When does VBI Vaccines report earnings?
  • Should I buy VBI Vaccines stock now?

What is the primary business of VBI Vaccines?

VBI Vaccines is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases and cancer. They use advanced technology to create safe and effective vaccine candidates, aiming to improve global health and address unmet medical needs.

What is the ticker symbol for VBI Vaccines?

The ticker symbol for VBI Vaccines is NASDAQ:VBIV

Does VBI Vaccines pay dividends?

No, VBI Vaccines does not pay dividends

What sector is VBI Vaccines in?

VBI Vaccines is in the Healthcare sector

What industry is VBI Vaccines in?

VBI Vaccines is in the Biotechnology industry

What country is VBI Vaccines based in?

VBI Vaccines is headquartered in United States

When did VBI Vaccines go public?

VBI Vaccines's initial public offering (IPO) was on 26 April 2010

Is VBI Vaccines in the S&P 500?

No, VBI Vaccines is not included in the S&P 500 index

Is VBI Vaccines in the NASDAQ 100?

No, VBI Vaccines is not included in the NASDAQ 100 index

Is VBI Vaccines in the Dow Jones?

No, VBI Vaccines is not included in the Dow Jones index

When was VBI Vaccines's last earnings report?

VBI Vaccines's most recent earnings report was on 14 August 2024

When does VBI Vaccines report earnings?

The date for VBI Vaccines's next earnings report has not been announced yet

Should I buy VBI Vaccines stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions